Summary

The analysis covered 1,430 authorisation records and found that 76.5% were reviewed by the FDA’s radiology panel. The authors use the result to highlight how clinical AI deployment remains concentrated in imaging workflows.

Why it matters

The finding provides a useful reality check on medical-AI adoption: authorisation volume is substantial, but it is unevenly distributed across specialties and evidence regimes.

Sources